Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel ...
If the oral arguments earlier this month offer any indication, the Supreme Court will uphold conversion therapy—and then some.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback